Status
Study
Lead sponsor
Phase
Enrol
UK sites
Start
Recruiting
Nurix Therapeutics, Inc.
Phase 1
345
Sutton, Cambridge, Glasgow, London, Manchester, Newcastle, Oxford
2021-09-29
Active, closed
Inhibrx Biosciences, Inc
Phase 2
206
London, Manchester, Oxford
2021-09-23
Active, closed
Janssen Research & Development, LLC
Phase 1
166
London, Manchester, Oxford, Surrey
2021-09-22
Active, closed
Loxo Oncology, Inc.
Phase 3
600
Birmingham, Leeds, Leicester, London, Oxford, Plymouth
2021-09-20
Recruiting
Amgen
Phase 3
60
Birmingham, Liverpool, Oxford
2021-09-09
Active, closed
Perspectum
Observational
1,030
Oxford
2021-07-06
Active, closed
Daiichi Sankyo
Phase 2
155
London, Nottingham, Oxford
2021-06-03
Recruiting
Eli Lilly and Company
Phase 3
150
London, Oxford, Sheffield
2021-05-26
By invitation
Cytokinetics
Phase 2/3
900
Birmingham, Dundee, Glasgow, Liverpool, London, Oxford
2021-05-06
Active, closed
Hoffmann-La Roche
Phase 2
586
Dundee, London, Newcastle, Oxford, Peterborough, Plymouth
2021-05-05
Active, closed
Hoffmann-La Roche
Phase 3
557
Birmingham, Liverpool, London, Manchester, Newcastle upon Tyne, Oxford
2021-04-26
Active, closed
Eli Lilly and Company
Phase 3
101
Bristol, Liverpool, Nottingham, Oxford, Stoke-on-Trent, Sheffield
2021-04-13
Active, closed
Geron Corporation
Phase 3
327
London, Oxford
2021-04-12
Active, closed
Novartis Pharmaceuticals
Phase 3
430
Edinburgh, Cardiff, Boston, Cambridge, Liverpool, London, Oxford
2021-04-09
Active, closed
Loxo Oncology, Inc.
Phase 3
500
Aberdeen, Plymouth, Newmarket, Glasgow, Nottingham, Oxford, Windsor
2021-04-08
Recruiting
Merck Sharp & Dohme LLC
Phase 2
490
Bristol, Nottingham, Windsor, London, Oxford, Newmarket, Sutton, Manchester
2021-04-05
Active, closed
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
496
London, Oxford, Sutton
2021-03-18
Active, closed
Karyopharm Therapeutics Inc
Phase 3
353
London, Oxford, Boston, Liverpool, Newcastle upon Tyne
2021-03-11
Active, closed
Celgene
Phase 3
313
Nottingham, Birmingham, Boston, Oxford
2021-02-25
Active, closed
Incyte Corporation
Phase 1
140
Boston, Lincoln, Manchester, Oxford
2021-02-23
Active, closed
Forma Therapeutics, Inc.
Phase 3
450
Leicester, London, Oxford, Sheffield
2021-01-29
Active, closed
Replimune, Inc.
Phase 1
123
Bebington, London, Oxford
2020-12-29
Active, closed
Pfizer
Phase 3
841
Newcastle upon Tyne, Sutton, Birmingham, London, Oxford
2020-12-21
Active, closed
Mirum Pharmaceuticals, Inc.
Phase 2
182
London, Oxford, Belfast, Birmingham, Cambridge, Edinburgh, Leeds, Newcastle upon Tyne
2020-12-18
Active, closed
Boston Scientific Corporation
Observational
250
Liverpool, Oxford
2020-12-16